Limitations, agreements, and source contact

Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma · Source last updated 2026-07-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

true

point Of Contact

email

eemanasanch@mdanderson.org

organization

UT MD Anderson Cancer Center

phone

713-745-8092

title

Dr. Elisabet Manasanch/ Assistant Professor, Lymphoma-Myeloma

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice